PBE

Invesco Dynamic Biotechnology & Genome ETF

Down$48.61
$-0.46
(-0.94%)
As of 12:00:00 AM EDT | 10/18/19  |  Market Closed

PBE Trading Data

Open

$49

Low Price

$48.2

High Price

$49

Previous Last Price

$49.07

Bid Size

$0 X 0

Ask Size

$0 X 0

PBE Portfolio Data

AUM

$216,040,000

Shares

4,400

PE Ratio

55.84

Price / Book Ratio

4.85

Expense Ratio

0.59

Net Asset Value

$49.10

Volume

Volume

4,100

Avg. Volume (YDT)

16,947

Dollar Volume

$0

Weekly Avg. Volume

11,440

Monthly Avg. Volume

9,315

Quarterly Avg. Volume

9,182

PBE Fund Description

The Invesco Dynamic Biotechnology and Genome ETF is based on the Dynamic Biotech and Genome Intellidex Index. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

PBE Chart

PBE Summary

Fund Family

Invesco

Tracks This Index

Invesco Dynamic Biotechnology & Genome ETF

Inception Date

2005-06-23

Asset Class

Equity

Asset Class Size

Biotech

PBE Classification

Region (General)

North America

Region (Specific)

US

Sector

Health Care

Equity Index

Leveraged Family

PBE Holdings

Top 10 Holdings

Celgene Corp (CELG)
5.35%
Biogen Inc (BIIB)
5.23%
Gilead Sciences Inc (GILD)
5.22%
Vertex Pharmaceuticals Inc (VRTX)
5.07%
Neurocrine Biosciences Inc (NBIX)
5.04%
Amgen Inc (AMGN)
5.02%
Incyte Corp (INCY)
4.79%
Alexion Pharmaceuticals Inc (ALXN)
4.55%
Myriad Genetics Inc (MYGN)
3.63%
Emergent BioSolutions Inc (EBS)
3.55%

Total PBE Holdings

Total Holdings: 31

Celgene Corp (CELG)
5.35%
Biogen Inc (BIIB)
5.23%
Gilead Sciences Inc (GILD)
5.22%
Vertex Pharmaceuticals Inc (VRTX)
5.07%
Neurocrine Biosciences Inc (NBIX)
5.04%
Amgen Inc (AMGN)
5.02%
Incyte Corp (INCY)
4.79%
Alexion Pharmaceuticals Inc (ALXN)
4.55%
Myriad Genetics Inc (MYGN)
3.63%
Emergent BioSolutions Inc (EBS)
3.55%
Natera Inc (NTRA)
3.23%
Arrowhead Pharmaceuticals Inc (ARWR)
2.92%
Radius Health Inc (RDUS)
2.9%
Nektar Therapeutics (NKTR)
2.85%
United Therapeutics Corp (UTHR)
2.75%
Xencor Inc (XNCR)
2.72%
Ironwood Pharmaceuticals Inc (IRWD)
2.7%
Vanda Pharmaceuticals Inc (VNDA)
2.7%
Halozyme Therapeutics Inc (HALO)
2.67%
Portola Pharmaceuticals Inc (PTLA)
2.64%
Genomic Health Inc (GHDX)
2.61%
Veracyte Inc (VCYT)
2.6%
Arena Pharmaceuticals Inc (ARNA)
2.52%
FibroGen Inc (FGEN)
2.46%
Coherus Biosciences Inc (CHRS)
2.44%
Exelixis Inc (EXEL)
2.43%
Enanta Pharmaceuticals Inc (ENTA)
2.37%
Repligen Corp (RGEN)
2.37%
Alkermes PLC (ALKS)
2.35%
Voyager Therapeutics Inc (VYGR)
2.33%
PowerShares Dynamic Biotech &Genome ETF (PBE)
0%

PBE Technicals

Alpha

-2.32

Beta

1.46

Leverage

Long

Standard Deviation

2.7

PBE Dividends

Dividend Date

2018-09-24

Latest Dividend

0.002

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

PBE Performance

YTD Return

3.27%

1 Year Return

-11.21%

3 Year Return

25.16%

5 Year Return

-0.37%

10 Year Return

217.72%

PBE Related Articles

© 2019 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.